Business Wire

Seagen to Highlight Research in Urothelial and Colorectal Cancers at 2022 European Society for Medical Oncology (ESMO) Congress

Share

Seagen Inc. (Nasdaq:SGEN) today announced upcoming presentations of new data from its clinical development programs at the European Society for Medical Oncology (ESMO) Congress 2022, to be held September 9-13 in Paris, France. One of two late-breaking oral presentations will feature results from Cohort K of EV-103 (also known as KEYNOTE-869), a phase 1b/2 clinical trial conducted in partnership with Astellas. Cohort K is evaluating PADCEV® (enfortumab vedotin-ejfv) as monotherapy or in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer (la/mUC) who are ineligible to receive cisplatin-based chemotherapy. Merck is known as MSD outside the United States and Canada.

A second late-breaking oral presentation will include additional results from the phase 2 MOUNTAINEER trial evaluating TUKYSA® (tucatinib) in combination with trastuzumab in patients with previously treated HER2-positive metastatic colorectal cancer (mCRC). Patient-reported outcomes from MOUNTAINEER also will be detailed in a separate presentation. Data from the MOUNTAINEER trial formed the basis of a supplemental New Drug Application submitted to the U.S. Food and Drug Administration (FDA) under the Accelerated Approval Program. On July 28, 2022, the FDA granted Breakthrough Therapy Designation for tucatinib in combination with trastuzumab for the treatment of adult patients with unresectable or metastatic HER2-positive CRC who have previously received fluoropyrimidine-, oxaliplatin- and irinotecan-containing chemotherapy. The designation is based on results from the MOUNTAINEER trial.

“These important data to be shared at the ESMO Congress reflect our commitment to develop innovative solutions for patients with challenging clinical needs in cancer,” said Marjorie Green, M.D., Senior Vice President and Head of Late-Stage Development at Seagen.

Presentations of Company-Sponsored Trials

ABSTRACT TITLE

PRESENTATION #

PRESENTATION TYPE

LEAD AUTHOR

PADCEV® (enfortumab vedotin-ejfv)

Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)

LBA73

Oral Presentation / Proffered Paper Session 2: GU Tumours, Non-prostate, September 12,

14:55-15:05 CEST

J. Rosenberg

TUKYSA® (tucatinib)

Additional analyses of MOUNTAINEER: A phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC

LBA27

Mini Oral Presentation / Mini Oral Session: GI, Lower Digestive, September 12, 14:50-14:55 CEST

J. H. Strickler

Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph 2 study MOUNTAINEER​

361P

Poster Session 7, September 11, 12:00-13:00 CEST

C. Wu

TUKYSA® (tucatinib) Trials in Progress

MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer (trial in progress)

438TiP

Poster Session 8, September 11, 12:00-13:00 CEST 

T. André 

Disitamab vedotin Trials in Progress

Phase 2 clinical study evaluating the efficacy and safety of disitamab vedotin in patients (pts) with HER2-expressing urothelial carcinoma (RC48G001, trial in progress)

1779TiP

Poster Session 12, September 12, 12:00-13:00 CEST

V. S. Koshkin

Health Economics and Outcomes Research

Impact of anti-EGFR therapies on HER2-positive metastatic colorectal cancer (HER2+ mCRC): A systematic literature review and meta-analysis of clinical outcomes

376P

 Poster Session 8, September 11, 12:00-13:00 CEST

T. S. Bekaii-Saab 

About Seagen

Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on our marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.

Forward-Looking Statements

Certain statements made in this press release are forward looking, such as those, among others, relating to the therapeutic potential of PADCEV, TUKYSA, disitamab vedotin and the company’s other products and product candidates, including their potential efficacy, safety and therapeutic uses, and the potential for TUKYSA to receive accelerated approval from the FDA based on data from the MOUNTAINEER trial. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, the possibility that data from the MOUNTAINEER trial and other trials may not be sufficient to support any regulatory approvals; the risk of adverse events, including the potential for newly-emerging safety signals; adverse regulatory actions; delays, setbacks or failures in clinical development activities, the submission of regulatory applications and the regulatory review process for a variety of reasons, including the difficulty and uncertainty of pharmaceutical product development. More information about the risks and uncertainties faced by Seagen is contained under the caption “Risk Factors” included in the company’s Quarterly Report on Form 10-Q for the year ended June 30, 2022 filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Media
David Caouette
(310) 430-3476
dcaouette@seagen.com

For Investors
Douglas Maffei, Ph.D.
(425) 527-4881
dmaffei@seagen.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

The LYCRA Company Announces Collaboration With Qore ® to Use QIRA ® for Next Generation Bio-derived LYCRA ® Fiber at Scale29.9.2022 02:00:00 CEST | Press release

The LYCRA Company,a global leader in developing innovative fiber and technology solutions for the textile and apparel industry, today announced it has entered into an agreement with Qore® to enable the world’s first large-scale commercial production of bio-derived spandex using QIRA®, the next generation 1,4-butanediol (BDO), as one of its main ingredients. This will result in 70% of the LYCRA® fiber content being derived from annually renewable feedstock. This change could potentially reduce the carbon footprint of LYCRA® fiber by up to 44%* versus equivalent product made from fossil-based resources, while maintaining the same high-quality performance parameters of traditional LYCRA® fiber. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220928005020/en/ The LYCRA Company signs an agreement with Qore® LLC to enable large-scale production of bio-derived spandex. Pictured – Julien Born, CEO of The LYCRA Company (left), and Jon

Mainstay Medical Announces Publication of Three-Year Patient Outcomes Data from ReActiv8-B Clinical Trial Demonstrating Long-Term Efficacy of ReActiv8® Restorative Neurostimulation ™28.9.2022 22:30:00 CEST | Press release

Mainstay Medical Holdings plc today announced the publication of the three-year patient outcomes data from its pivotal ReActiv8-B clinical trial. The data, published in the journal of the International Neuromodulation Society, Neuromodulation,further establish the efficacy and safety of ReActiv8 Restorative Neurostimulation, including compelling long-term durability and improvement over time on key outcome measures in the treatment of intractable chronic low back pain. The three-year data show improvements over results from the patients’ one-year and two-year visits on virtually all key efficacy measures. Of note: Outcome measure 1-year result (N = 176) 2-year result (N = 156) 3-year result (N = 133) Patients reporting pain intensity (Visual Analog Scale (VAS) score) reduced by 50% or more from baseline 64% 71% 77% Patients reporting a greater than 20-point reduction in Oswestry Disability Index 57% 61% 63% Patients reporting VAS score < 2.5 52% 65% 67% Patients taking opioids at basel

New Study From Egon Zehnder and Kearney Debunks the Myth of a Workplace Generational Divide28.9.2022 16:00:00 CEST | Press release

Egon Zehnder, the world’s preeminent leadership advisory firm, in partnership with Kearney, a leading global management consulting firm, today released findings from a new survey with over 8,000 respondents from eight different countries dismissing the myth of a generation divide in the workplace and showing that despite what is often believed, Gen Z, Millennials, Gen X and Boomers are more alike than different when it comes to workplace matters. The survey, titled “Different Generations, Same Ideals: What Workers of All Ages Value in their Jobs,” analyzed the similarities and differences among generations and found that they share more commonalities, especially when it comes to personal well-being, work-life balance, and desired traits from leadership. The most notable difference between the generations is how each group defines and plans to achieve their career desires. Key Findings from the survey include: Personal well-being, stability, and work-life balance matter more than money

BYD Announces Pre-sale Prices of European Passenger Car Range28.9.2022 15:35:00 CEST | Press release

BYD announces the pre-sale prices of its new European passenger car range. The world’s leading manufacturer of new energy vehicles and power batteries immediately introduces three full-electric passenger vehicles which will be delivered to Norway, Sweden, Denmark, the Netherlands, Belgium, Luxembourg and Germany. Before the end of the year customers in France and the United Kingdom will also have access to BYD’s zero-emission vehicles. After that, more dealers will be appointed supporting BYD’s plans to cover all major markets in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220928005587/en/ BYD Europe Product Premiere 2022 The pre-sale price for the BYD ATTO 3 is € 38,000. The BYD HAN and TANG pre-sale prices are € 72,000. These pre-sale prices apply to Germany as a reference for Europe and may differ from country to country. The three full-electric BYD vehicles are technologically advanced and well-suited to the e

Monrol Will Establish a Legal Entity and Manufacturing Facility in Germany28.9.2022 15:27:00 CEST | Press release

Following an ongoing assessment of its entire operation, Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has decided to establish a legal entity and manufacturing facility in Germany. The new facility will focus on the manufacture of SPECT products and radiopharmaceutical products for radioligand therapy(*) such as Gallium-68 generator and n.c.a Lutetium-177. Developed by Monrol R&D teams, these products are widely used in the production of radiopharmaceuticals for cancer patients. The facility will also have a dedicated division for state-of-the art cGMP Contract Development and Manufacturing Organization (CDMO) services. Monrol plans to make the site a center of excellence for both radiopharmaceutical production and scientific and industry collaborative efforts to create innovations. The facility is expected to be up and running by 2026 at an estimated cost of around 30 million euros. (*) Targeted radioligand therapy is an innovative approach to cancer treatment that is considered to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom